Hemophagocytic Lymphohistiocytosis Diagnosis and Management

Clinical Features and Diagnosis

• HLH presents as a severe hyperinflammatory syndrome with unremitting fever, cytopenias, hepatosplenomegaly, and markedly elevated ferritin levels, often progressing to multiorgan failure with high mortality if untreated, according to the National Comprehensive Cancer Network 1, 2
• Fever is nearly universal in HLH patients, characterized by high, persistent, unremitting fever 1
• Hepatosplenomegaly is characteristic of HLH, though may be absent in some secondary forms 1
• Cytopenias affecting two or more cell lines (anemia, thrombocytopenia, neutropenia) are common in HLH patients 1
• Neurologic involvement, including headaches, vision disturbances, gait abnormalities, altered mental status, and seizures, can occur in HLH patients 1
• Multiorgan dysfunction, including hepatitis with elevated transaminases and bilirubin, coagulopathy with hypofibrinogenemia, pulmonary edema, and renal dysfunction, is a hallmark of HLH 1, 2
• Hyperferritinemia, with rapidly rising ferritin >5000 ng/mL, is highly suggestive of HLH 1, 2
• Elevated inflammatory markers, including CRP, IL-6, INF-γ, and sIL-2Ra (soluble CD25), are often present in HLH patients 1
• Diagnosis requires fulfilling at least 5 of 8 HLH-2004 criteria, including fever, splenomegaly, cytopenias, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis, low NK cell activity, elevated ferritin, and elevated soluble CD25, as recommended by Praxis Medical Insights 3

Etiology

• Secondary HLH arises from immune triggers in the absence of primary genetic defects, though some patients may have unidentified genetic predispositions, according to the National Comprehensive Cancer Network 1
• Malignancy-associated HLH is particularly associated with T-cell and NK-cell lymphomas, B-cell lymphomas, and Castleman disease, as noted by Praxis Medical Insights 2
• Autoimmune/autoinflammatory disorders, such as systemic juvenile idiopathic arthritis, adult-onset Still's disease, and systemic lupus erythematosus, can trigger HLH, as reported by Praxis Medical Insights 4
• Iatrogenic causes, including CAR T-cell therapy, can also lead to HLH, with an incidence of 3.5% in CAR T-cell therapy, according to the National Comprehensive Cancer Network 1

Management

• For most secondary HLH cases, initiate high-dose corticosteroids (methylprednisolone 1g/day IV for 3-5 consecutive days) as first-line therapy while simultaneously treating the underlying trigger, as recommended by Praxis Medical Insights 2, 3
• Corticosteroids, such as methylprednisolone 1g/day IV for 3-5 days, are the cornerstone of first-line treatment for HLH, according to Praxis Medical Insights 2, 3
• Treat underlying causes, including antimicrobials for infection-triggered HLH, chemotherapy for malignancy-associated HLH, and disease-modifying therapy for MAS, as recommended by Praxis Medical Insights 2, 3
• Second-line treatment options include cyclosporine A, anakinra, and etoposide, which can be effective in MAS and malignancy-associated HLH, according to Praxis Medical Insights 2, 3
• Tocilizumab, an anti-IL-6 therapy, is particularly effective in CAR T-cell-induced HLH/MAS, as reported by the National Comprehensive Cancer Network 1, 2
• Rituximab can be used to treat EBV-triggered HLH, as noted by Praxis Medical Insights 2
• Etoposide can be used as a last resort for refractory cases, though it carries significant toxicity, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2

Critical Care Management

• Patients with shock at ICU admission, platelet count <30 g/L, grade ≥3 neurotoxicity, or severe organ dysfunction require ICU-level care with frequent reassessment every 12 hours, as recommended by Praxis Medical Insights 2, 3
• Supportive care, including mechanical ventilation, vasopressors, renal replacement therapy, and transfusions, is essential in the management of critical HLH patients, according to Praxis Medical Insights 2, 3
• Monitoring of inflammatory parameters, organ function, and cytokine levels is crucial in the management of HLH, as recommended by Praxis Medical Insights 2, 3
• Antifungal prophylaxis should be strongly considered in patients receiving prolonged corticosteroids, as noted by the National Comprehensive Cancer Network 5

Prognostic Factors

• Factors associated with higher mortality include shock at ICU admission, platelet count <30 g/L, and malignancy-associated HLH, as reported by Praxis Medical Insights 2

Critical Pitfalls to Avoid

• Delayed diagnosis and treatment significantly increase mortality, and a high index of suspicion should be maintained in patients with persistent fever, cytopenias, and ferritin >5000 ng/mL, as recommended by Praxis Medical Insights 2, 3
• Empirical treatment should not be delayed while waiting for all HLH-2004 criteria to be met, according to the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2
• Underlying triggers, such as infections or malignancies, should not be neglected in the treatment of HLH, as noted by Praxis Medical Insights 2, 3
• Pediatric protocols should not be directly applied to adults, and dose adjustments and different considerations are required, as recommended by Praxis Medical Insights 2
• CNS involvement should not be overlooked, and lumbar puncture should be performed if grade 3-4 neurotoxicity is present, according to the National Comprehensive Cancer Network 5
• ICU transfer should not be delayed in patients with grade ≥2 organ dysfunction, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 3

Hemophagocytic Lymphohistiocytosis (HLH) Diagnosis and Clinical Presentation

Laboratory Abnormalities

• Hypertriglyceridemia, hypofibrinogenemia, elevated soluble CD25, elevated transaminases, LDH, d-dimers, decreased albumin and sodium are characteristic laboratory abnormalities in HLH patients 6
• Splenomegaly is a diagnostic criterion for HLH 6

Age-Related Differences

• Primary HLH is most common in children, though can occur in adolescents and young adults, as reported by Haematologica 6

HLH Presenting with Cholestatic Liver Pattern: Diagnostic and Management Considerations

Clinical Presentation and Diagnostic Challenges

• Hepatic dysfunction in HLH manifests as elevated transaminases, bilirubin, coagulopathy with hypofibrinogenemia, and hepatosplenomegaly, as recommended by the American Society of Hematology 7, 8
• The European Hematology Association notes that multiple HLH diagnostic criteria overlap with primary liver disease manifestations, making differentiation from viral hepatitis, autoimmune hepatitis, or drug-induced liver injury challenging 9, 10

Diagnostic Criteria and Clues

• Markedly elevated ferritin (>5,000-10,000 μg/L) in the context of cholestatic liver injury should immediately raise suspicion for HLH, according to the American Society of Hematology 11
• Progressive cytopenias affecting ≥2 cell lines despite supportive care is a critical diagnostic clue, as noted by the European Hematology Association 11
• Hypertriglyceridemia and hypofibrinogenemia disproportionate to liver dysfunction alone is a key diagnostic feature, as recommended by the American Society of Hematology 11
• Elevated soluble CD25 (sCD25 ≥2,400 U/mL) provides strong supportive evidence for HLH, according to the European Hematology Association 11

Management Algorithm

• The American Society of Hematology recommends immediate diagnostic workup, including complete HLH-2004 criteria assessment, bone marrow aspiration, comprehensive infectious workup, and malignancy screening 7, 11
• The European Hematology Association suggests that empirical HLH treatment should not be delayed while awaiting all diagnostic criteria if clinical suspicion is high with ferritin >10,000 μg/L, progressive cytopenias, and cholestatic injury 9, 10
• The American College of Gastroenterology recommends avoiding liver biopsy in suspected HLH with coagulopathy due to bleeding risk; diagnosis can be established with bone marrow and clinical criteria 12, 11

Prognostic Factors and Monitoring

• The European Hematology Association notes that factors associated with progression to fulminant hepatic failure and higher mortality include shock at presentation, platelet count <30 g/L, malignancy-associated HLH, and delayed diagnosis and treatment initiation 9, 10
• The American Society of Hematology recommends monitoring ferritin, triglycerides, fibrinogen, complete blood counts, and liver function tests every 12-24 hours to assess response to treatment 7, 8

Early Autoimmune Disease vs Hemophagocytic Lymphohistiocytosis (HLH): Cited Diagnostic and Management Facts

1. Pathophysiologic Distinction

• Early autoimmune disorders (e.g., systemic lupus erythematosus, adult‑onset Still’s disease, drug‑induced immune reactions) generate a hyperinflammatory state with fever, cytopenias, and hyperferritinemia, but they usually lack the extreme cytokine storm, NK‑cell dysfunction, and overt hemophagocytosis required for a full HLH diagnosis. – American Society of Hematology 13, 14

2. Laboratory Features that Differentiate HLH from Early Autoimmunity

Ferritin

• Autoimmune‑related hyperferritinemia typically ranges 1,000–5,000 µg/L, whereas true HLH often produces ferritin ≥7,000–10,000 µg/L; levels >10,000 µg/L are >90 % sensitive and specific for HLH in children and highly suggestive in adults. – American Society of Hematology 13, 14
• Early autoimmune processes rarely reach these extreme ferritin thresholds. – American Society of Hematology 13

NK‑Cell Activity

• Low or absent NK‑cell activity is a specific HLH criterion and is normally preserved in early autoimmune disease. – American Society of Hematology 13, 14

Soluble IL‑2 Receptor (sCD25)

• HLH requires sCD25 ≥2,400 U/mL, reflecting intense T‑cell activation; autoimmune diseases may show modest elevation but rarely meet this cutoff. – American Society of Hematology 13, 14
• The area under the ROC curve for sCD25 is 0.90 for adult HLH diagnosis, outperforming ferritin (AUC 0.78). – American Society of Hematology 13

Lipid and Coagulation Markers

• HLH diagnostic thresholds: fasting triglycerides ≥3.0 mmol/L (≥265 mg/dL) and/or fibrinogen ≤1.5 g/L; early autoimmune disease may have mild abnormalities but does not usually produce such severe hypertriglyceridemia or consumptive hypofibrinogenemia. – American Society of Hematology 13, 14

Hemophagocytosis

• Present in only 51–60 % of confirmed HLH cases at initial presentation; its absence does not exclude HLH. – American Society of Hematology 13
• Hemophagocytosis can also occur in autoimmune disease, severe infection, and other inflammatory states, limiting its specificity. – European Hematology Association 15

3. Clinical Overlap Between Early Autoimmune Disease and HLH

• Fever >38.5 °C occurs in >90 % of HLH and is universal in active autoimmune disease. – American Society of Hematology 13
• Cytopenias affecting ≥2 lineages are common to both SLE and HLH. – American Society of Hematology 13
• Splenomegaly and elevated liver enzymes are observed in both conditions. – American Society of Hematology 13

4. Diagnostic Tools

HScore

• An HScore > 169 confers >93 % probability of HLH. – American Society of Hematology 13
• An HScore of 90–168 corresponds to a 75–93 % probability of HLH. – American Society of Hematology 13
• The HScore integrates: underlying immunosuppression, temperature, organomegaly, number of cytopenias, ferritin level, triglycerides, fibrinogen, AST, and presence of hemophagocytosis. – American Society of Hematology 13

Clinical Judgment

• HLH‑directed therapy may be initiated even when fewer than five HLH‑2004 criteria are met if clinical suspicion is high. – American Society of Hematology 14

5. Triggers and Recommended Work‑up

• Autoimmune‑associated HLH (macrophage activation syndrome) is a distinct entity where the underlying autoimmune disease precipitates secondary HLH. – American Society of Hematology 14
• Adult‑onset Still’s disease is a well‑recognized trigger for MAS/HLH. – American Society of Hematology 14
• Screen for occult malignancy (especially lymphoma) with CT of chest/abdomen/pelvis and consider PET imaging. – American Society of Hematology 14; European Hematology Association 15
• Comprehensive infectious evaluation (EBV, CMV, HIV, fungal pathogens) is essential, as viral infections frequently act as co‑triggers. – American Society of Hematology 14
• Medication review to identify drug‑induced immune activation as a possible trigger. – American Society of Hematology 14

6. Monitoring and Pitfalls

• Serial monitoring of ferritin, platelet count, and clinical status every 12 hours is recommended to track disease trajectory. – European Hematology Association 15
• Absence of hemophagocytosis on initial bone‑marrow aspirate does not rule out HLH; it may be missing in up to 49 % of cases. – European Hematology Association 15
• Rapid rise of ferritin (rather than a single absolute value) is a key dynamic marker of active HLH. – European Hematology Association 15
• Integration of all clinical and laboratory features is required to avoid misattributing HLH findings solely to the underlying autoimmune disease. – American Society of Hematology 13; European Hematology Association 15
• Viral co‑triggers (EBV, CMV) are common in autoimmune‑associated HLH; a thorough infectious work‑up is mandatory. – American Society of Hematology 14